nach oben

Erschienen in:

01.07.2014 | Review

Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis

verfasst von: Federica Zoratto, Luigi Rossi, Monica Verrico, Anselmo Papa, Enrico Basso, Angelo Zullo, Luigi Tomao, Adriana Romiti, Giuseppe Lo Russo, Silverio Tomao

Erschienen in: Tumor Biology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Originally, colorectal cancer (CRC) tumorigenesis was understood as a multistep process that involved accumulation of tumor suppressor genes and oncogenes mutations, such as APC, TP53 and KRAS. However, this assumption proposed a relatively limited repertoire of genetic alterations. In the last decade, there have been major advances in knowledge of multiple molecular pathways involved in CRC pathogenesis, particularly regarding cytogenetic and epigenetic events. Microsatellite instability, chromosomal instability and CpG island methylator phenotype are the most analyzed cytogenetic changes, while DNA methylation, modifications in histone proteins and microRNAs (miRNAs) were analyzed in the field of epigenetic alterations. Therefore, CRC development results from interactions at many levels between genetic and epigenetic amendments. Furthermore, hereditary cancer syndrome and individual or environmental risk factors should not be ignored. The difficulties in this setting are addressed to understand the molecular basis of individual susceptibility to CRC and to determine the roles of genetic and epigenetic alterations, in order to yield more effective prevention strategies in CRC patients and directing their treatment. This review summarizes the most investigated biomolecular pathways involved in CRC pathogenesis, their role as biomarkers for early CRC diagnosis and their possible use to stratify susceptible patients into appropriate screening or surveillance programs.

Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62(1):10–29.PubMed

Sengupta N, Gill KA, MacFie TS, Lai CS, Suraweera N, McDonald S, et al. Management of colorectal cancer: a role for genetics in prevention and treatment? Pathol Res Pract. 2008;204(7):469–77.PubMed

Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011;2011:792362.PubMedCentralPubMed

Kinzler KW, Vogelstein B. Cancer susceptibility genes. Gatekeepers and caretakers. Nature. 1997;386(6627):761–3.PubMed

Karen E. Kim; Early detection and prevention of colorectal cancer. Slack Incorporated 2009.

Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15(7):699–731.PubMedCentralPubMed

Kahng LS. Genetic aspects of non-polypoid colorectal neoplasms. Gastrointest Endosc Clin N Am. 2010;20(3):573–8.PubMed

Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int. 2012;2012:509348.

Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev. 2010;31(2):31–8.PubMedCentralPubMed

10.

Costedio M, Church J. Pathways of carcinogenesis are reflected in patterns of polyp pathology in patients screened for colorectal cancer. Dis Colon Rectum. 2011;54(10):1224–8.PubMed

11.

Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479–507.PubMed

12.

Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.PubMed

13.

Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138(6):2059–72.PubMedCentralPubMed

14.

Huang D, Du X. Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination. World J Gastroenterol. 2008;14(12):1823–7.PubMedCentralPubMed

15.

Booth RA. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007;249(1):87–96.PubMed

16.

De Roock W, Biesmans B, De Schutter J, Tejpar S. Clinical biomarkers in oncology: focus on colorectal cancer. Mol Diag Ther. 2009;13(2):103–14.

17.

Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene. 2010;29(21):3033–43.PubMed

18.

Douillard YJ, Oliner KS, Siena S, et al. N Engl J Med. 2013;369(11):1023–34.PubMed

19.

Vogelstein B, Fearon ER, Hamilta SR, et al. N Engl J Med. 1988;319:525–32.PubMed

20.

21.

Jen J, Kim H, Piantadosi S, et al. N Engl J Med. 1994;331:213–21.PubMed

22.

Kanthan R, Senger AL, Kanthan C. Molecular events in primary and metastatic colorectal carcinoma: a review. Pathol Res Int. 2012;2012:597497.

23.

Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2404–60.

24.

Cahill DP, Lengauer C, Yu J, et al. Nature. 1998;392(6673):300–3.PubMed

25.

Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13–27.PubMedCentralPubMed

26.

Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113–30.PubMed

27.

Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2009;31(1):27–36.PubMedCentralPubMed

28.

Esteller M. Molecular origins of cancer: epigenetics in cancer. N Engl J Med. 2008;358(11):1148–096.PubMed

29.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMed

30.

Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079–99.PubMedCentralPubMed

31.

Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073–87.PubMedCentralPubMed

32.

Iacopetta B, Grieu F, Amanuel B. Microsatellite instability in colorectal cancer. Asia-Pac J Clin Oncol. 2010;6(4):260–9.PubMed

33.

De la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380–7.PubMedCentralPubMed

34.

De la Chapelle A. Microsatellite instability. N Engl J Med. 2003;349(3):209–2010.PubMed

35.

Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132(1):127–38.PubMed

36.

Yim KL. Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome. Med Oncol. 2012;29(3):1796–801.PubMed

37.

Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer. Gastroenterology. 2008;135(4):1079–99.PubMedCentralPubMed

38.

Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, et al. Colorectal cancer: a tale of two sides, or a continuum? Gut. 2012;61(6):794–7.PubMedCentralPubMed

39.

Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–79.PubMed

40.

Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009;8:102.PubMedCentralPubMed

41.

Goel A, Boland CR. Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol. 2010;26(1):47–52.PubMedCentralPubMed

42.

de Krijger I, Mekenkamp LJM, Punt CJA, Nagtegaal ID. MicroRNAs in colorectal cancer metastasis. J Pathol. 2011;224:438–47.PubMed

43.

Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer. World J Surg. 2009;33(4):638–46.PubMed

44.

Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28(10):1057–68.PubMed

45.

Wong JJL, Hawkins NJ, Ward RL. Colorectal cancer: a model for epigenetic tumorigenesis. Gut. 2007;56(1):140–8.PubMedCentralPubMed

46.

Venkatachalam R, Ligtenberg MJ, Hoogerbrugge N, de Bruijn DR, Kuiper RP. Geurts van Kessel, A. The epigenetics of (hereditary) colorectal cancer. Cancer Genet Cytogenet. 2010;203(1):1–6.PubMed

47.

Kim YS, Deng G. Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia. Gut Liver. 2007;1(1):1–11.PubMedCentralPubMed

48.

Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis. 2007;28(9):1985–90.PubMed

49.

Raptis S, Mrkonjic M, Green RC, Pethe VV, Monga N, Chan YM, et al. MLH1-93G > A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst. 2007;99(6):463–74.PubMed

50.

Samowitz WS, Curtin K, Wolff RK, Albertsen H, Sweeney C, Caan BJ, et al. The MLH1-93 G > A promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes Chromosome Cancer. 2008;47(10):835–44.

51.

Burgess DJ. Gene expression: colorectal cancer classification. Nat Rev Cancer. 2013;13(6):380–1.PubMed

52.

Sadanandam A, Lyssiotis CA, Homicsko H, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619–25.PubMedCentralPubMed

53.

De Sosa E, Melo F, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614–8.

54.

Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102(6):365–7.PubMedCentralPubMed

55.

Ogino S, Chan AT, Fuchs S, Giovannucci E. Molecular Pathologic epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60(3):397–411.PubMedCentralPubMed

56.

Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-Low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006;8(5):582–8.PubMedCentralPubMed

57.

Hinoue T, Weisenberger JD, Lange CPE, Shen H, Byun HM, van den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22(2):271–82.PubMedCentralPubMed

58.

Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A. 2007;104(47):18654–9.PubMedCentralPubMed

59.

Issa JP. Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res. 2003;9(8):2879–81.PubMed

60.

Shen L, Catalano PJ, Benson AB, O’Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res. 2007;13(20):6093–8.PubMedCentralPubMed

61.

Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, Ruszkiewicz AR, et al. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut. 2006;55(10):1467–74.PubMedCentralPubMed

62.

Chirieac LR, Shen L, Catalano PJ, Issa JP, Hamilton SR. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am J Surg Pathol. 2005;29:429–36.PubMed

63.

Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1–10.PubMed

64.

Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044–58.PubMedCentralPubMed

65.

Gonzalez CA, Riboli E. Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer. 2010;46:2555–62.PubMed

66.

Hiraoka S, Kato J, Fujiki S, Kaji E, Morikami T, Nawa T, et al. The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology. 2010;139:1503–10.PubMed

67.

Hoffmeister M, Schmitz S, Karmrodt E, Stegmaier C, Haug U, Arndt V, et al. Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer. Clin Gastroenterol Hepatol. 2010;8:870–6.PubMed

68.

Huang L, Wang X, Gong W, Huang Y, Jiang B. The comparison of the clinical manifestations and risk factors of colorectal cancer and adenomas: results from a colonoscopy-based study in southern Chinese. Int J Color Dis. 2010;25:1343–51.

69.

Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer. 2006;119:2657–64.PubMed

70.

Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol. 2010;24:417–25.PubMed

71.

Schernhammer ES, Giovannucci E, Kawasaki T, Rosner R, Fuchs CS, Ogino S. Dietary folate, alcohol, and B vitamins in relation to line-1 hypomethylation in colon cancer. Gut. 2010;59:794–9.PubMedCentralPubMed

72.

Dahm CC, Keogh RH, Spencer EA, Greenwood DC, Key TJ, Fentiman IS, et al. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. J Natl Cancer Inst. 2010;102:614–26.PubMed

73.

Hildebrand JS, Jacobs EJ, Campbell PT, McCullough ML, Teras LR, Thun MJ, et al. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev. 2009;18:2835–41.PubMed

74.

Kim DH, Smith-Warner SA, Spiegelman D, Yaun SS, Colditz GA, Freudenheim JL, et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control. 2010;21:1919–30.PubMedCentralPubMed

75.

Burt RW, Leppert MF, Slattery ML, Samowitz WS, Spirio LN, Kerber RA, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology. 2004;127:44–51.

76.

Slattery ML, Curtin K, Sweeney C, Levin TR, Potter J, Wolff RK, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer. 2007;120(3):656–63.PubMed

77.

Satia JA, Keku T, Galanko JA, Martin C, Doctolero RT, Tajima A, et al. Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study. Cancer Epidemiol Biomarkers Prev. 2005;14:429–36.PubMed

78.

Campbell PT, Jacobs ET, Ulrich CM, Figueiredo JC, Poynter JN, McLaughlin JR, et al. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst. 2010;17:391–400.

79.

Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, et al. Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses’ health study. J Natl Cancer Inst. 2012;104:415–20.PubMedCentralPubMed

80.

Morikawa T, Kuchiba A, Lochhead P, Nishihara R, Yamauchi M, Imamura Y, et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with b-catenin (CTNNB1) status. Cancer Res. 2013;73(5):1600–10.PubMedCentralPubMed

81.

Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 2006;98(23):1731–8.PubMed

82.

Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;21(102):1012–22.

83.

Nishihara R, Morikawa T, Kuchiba A, Lochhead P, Yamauchi M, Liao X, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol. 2013;1(178):84–100.

84.

Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309(24):2563–71.PubMedCentralPubMed

85.

Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131–42.PubMed

86.

Rizzo A, Pallone F, Monteleone G, Fantini MC. Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol. 2011;17:3092–100.PubMedCentralPubMed

87.

Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (tam) and inflammation in colorectal cancer. Cancer Microenviron. 2011;4:141–54.PubMedCentralPubMed

88.

Mueller MM, Fusenig NE. Friends or foes—Bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839–49.PubMed

89.

Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.PubMedCentralPubMed

90.

Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–33.PubMed

91.

Curtin K, Slattery ML, Ulrich CM, Bigler J, Levin TR, Wolff RK, et al. Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis. 2007;28(8):1672–9.PubMedCentralPubMed

92.

Keku T, Millikan R, Worley K, Winkel S, Eaton A, Biscoco L, et al. 5,10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1611–21.PubMed

93.

Levine AJ, Siegmund KD, Ervin CM, Diep A, Lee ER, Frankl HD, et al. The methylenetetrahydrofolate reductase 677C → T polymorphism and distal colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2000;9(7):657–63.PubMed

94.

Yamaji T, Iwasaki M, Sasazuki S, Sakamoto H, Yoshida T, Tsugane S. Methionine synthase A2756G polymorphism interacts with alcohol and folate intake to influence the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2009;18(1):267–74.PubMed

95.

Iacopetta B, Heyworth J, Girschik J, Grieu F, Clayforth C, Fritschi L. The MTHFR C677T and ΔDNMT3B C-149 T polymorphisms confer different risks for right- and left-sided colorectal cancer. Int J Cancer. 2009;125(1):84–90.PubMed

96.

Mokarram P, Kumar K, Brim H, Naghibaldhossaini F, Saberi-froozi M, Nouraie M, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS One. 2009;4(9):e7012.PubMedCentralPubMed

97.

Zeisel SH. Gene response elements, genetic polymorphisms and epigenetics influence the human dietary requirement for choline. IUBMB Life. 2007;59(6):380–7.PubMedCentralPubMed

98.

Van Engeland M, Weijenberg MP, Roemen GMJM, Brink M, De Bruine AP, Goldbohm RA, et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 2003;63(12):3133–7.PubMed

99.

Hamid A, Kiran M, Rana S, Kaur J. Low folate transport across intestinal basolateral surface is associated with down-regulation of reduced folate carrier in in vivo model of folate malabsorption. IUBMB Life. 2009;61(3):236–43.PubMed

100.

Paun BC, Kukuruga D, Jin Z, Mori Y, Cheng Y, Duncan M, et al. Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. Cancer. 2010;116(19):4495–501.PubMedCentralPubMed

101.

102.

Hughes LAE, van den Brandt PA, de Bruïne AP, Wouters KA, Hulsmans S, Spiertz A, et al. Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms. PLoS One. 2009;4(11):e7951.PubMedCentralPubMed

103.

Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1–18.PubMedCentralPubMed

104.

Plaschke J, Engel C, Kruger S, Holinski-Feder E, Pagenstecher C, Mangold E, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic msh6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol. 2004;22:4486–94.PubMed

105.

Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.PubMedCentralPubMed

106.

Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.PubMed

107.

Burn J. Aspirin prevents cancer in Lynch syndrome. Eur J Cancer. 2009;7:320–1.

108.

Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–9.PubMed

109.

Juhn E, Khachemoune A. Gardner syndrome: skin manifestations, differential diagnosis and management. Am J Clin Dermatol. 2010;11(2):117–22.PubMed

110.

Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol. 2007;61:153–61.PubMed

111.

McGarrity TJ, Amos C. Peutz–Jeghers syndrome: clinicopathology and molecular alterations. Cell Mol Life Sci. 2006;63(18):2135–44.PubMed

112.

Calva D, Howe JR. Hamartomatous polyposis syndromes. Surg Clin N Am. 2008;88(4):779–817.PubMedCentralPubMed

113.

Kaemmerer E, Klaus C, Jeon MK, Gassler N. Molecular classification of colorectal carcinomas: the genotype to phenotype relation. World J Gastroenterol. 2013;19(45):8163–7.PubMedCentralPubMed

114.

Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088–100.PubMed

115.

East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol Clin N Am. 2008;37:25–46.

116.

Fanali C, Lucchetti D, Farina M, Corbi M, Cufino V, Cittadini A, et al. Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World J Gastroenterol. 2014;20(4):923–42.PubMedCentralPubMed

117.

Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124(2):544–60.PubMed

118.

Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology. 2005;128(1):192–206.PubMed

119.

Hardcastle JD, Thomas WM, Chamberlain J, Pye G, Sheffield J, James PD, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer: results for first 107,349 subjects. Lancet. 1989;1(8648):1160–4.PubMed

120.

Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005;97(15):1107–9.PubMed

121.

Creeden J, Junker F, Vogel-Ziebolz S, Rex D. Serum tests for colorectal cancer screening. Mol Diagn Ther. 2011;15(3):129–41.PubMed

122.

Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010;29(1):181–206.PubMed

123.

Wong JJL, Hawkins NJ, Ward RL, Hitchins MP. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2011;24(3):396–411.PubMed

124.

Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93:851–65.

125.

Alquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening]by detection of altered human DNA in stool; feasibility of a mutitarget assay panel. Gastroenterology. 2000;119:1219–27.

126.

Calistri D, Rengucci C, Bocchini R, et al. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol. 2003;1:377–83.PubMed

127.

Roperch JP, Incitti R, Forbin F, et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013;13:566.PubMedCentralPubMed

128.

Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116.PubMedCentralPubMed

129.

Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–59.PubMedCentralPubMed

130.

Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010;29(1):181–206.PubMed

131.

Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079–99.PubMedCentralPubMed

132.

Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113–30.PubMed

Titel: Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis
verfasst von: Federica Zoratto
Luigi Rossi
Monica Verrico
Anselmo Papa
Enrico Basso
Angelo Zullo
Luigi Tomao
Adriana Romiti
Giuseppe Lo Russo
Silverio Tomao
Publikationsdatum: 01.07.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 7/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1845-9

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis

Abstract

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2014

Aberrant promoter methylation of the vimentin gene may contribute to colorectal carcinogenesis: a meta-analysis

Association of endothelia nitric oxide synthase gene rs1799983 polymorphism with susceptibility to prostate cancer: a meta-analysis

Comment on Gu et al. entitled “Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis”

Diagnostic accuracy of contrast-enhanced ultrasound for renal cell carcinoma: a meta-analysis

Antitumor activity of a polysaccharide from longan seed on lung cancer cell line A549 in vitro and in vivo

Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1α-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie